Teva Pharma (TEVA) Cut to Junk by S&P; to BB/Stable from BBB-/Watch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Teva Pharma (TEVA) PT Lowered to $23 at Goldman Sachs; Remains Bullish as Expectations Reset
February 9, 2018 8:52 AM ESTGoldman Sachs lowered its price target on Teva Pharma (NYSE: TEVA) to $23.00 (from $25.00) while maintaining a Buy rating following the company's 4Q earnings and meetings with management.
While 2018 guidance came in lower than expected, analyst Jami Rubin believes it helps reset investor expectations and,... More
Teva Pharma (TEVA) PT Lowered to $16.50 at Wells Fargo
February 9, 2018 8:05 AM ESTWells Fargo lowered its price target on Teva Pharma (NYSE: TEVA) to $16.50 (from $17.00) while maintaining an Underperform rating.
"We believe the conference call went poorly and reinforced worries about the weak 2018 guidance," analyst David Maris commented.
Lowers FY 2018 EPS to $2.43, which compares to Tevas guidance of $2.25-2.50.
... More